Latest Steps In FDA Homeopathy Policy Overhaul Prompt Trade Group Questions

A revised draft introduces list of risk-based enforcement priorities but doesn't necessarily tighten FDA oversight of homeopathics manufacturing and marketing, say CHPA and AIH.

Homeopathy_vials_14884009_1200.jpg

The margin for error in the US homeopathic industry could spread rather than shrink with the Food and Drug Administration withdrawing a policy guide that for three decades allowed sales of the products before it finalizes a guidance on compliance with agency regulations.

In the revised draft guidance it published the same day it withdrew Compliance Policy Guide 400.400 adopted in 1988,...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation